Cibus, INC

Cibus, Inc. announced leadership changes with Craig Wichner appointed as CEO, succeeding Peter Beetham who returns to President and COO role, as part of a succession plan.

Cibus, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of nine directors and the ratification of its independent auditor.

Cibus, Inc. announced its first quarter 2026 financial results, highlighting progress in its Rice herbicide tolerance and Sustainable Ingredients programs, alongside positive regulatory developments and a strengthened balance sheet.

Cibus, Inc. announced the appointment of Thomas Urban to its Board of Directors, effective April 7, 2026, bringing extensive agribusiness and finance experience.

Cibus, Inc. announced an underwritten public offering of 6.98 million shares of Class A common stock at $2.15 per share, aiming to raise approximately $13.5 million in net proceeds.

Cibus, Inc. announced its Q4 and full-year 2025 financial results, highlighting significant progress in gene-editing technology and commercialization efforts for its plant traits.

Cibus Inc. reported a 63% increase in Q1 2026 revenue to $1.7 million, driven by collaboration agreements, while net losses narrowed significantly due to cost reductions and a prior year goodwill impairment.

Cibus, Inc. reported reduced net losses and increased cash reserves for the nine months ended September 30, 2025, driven by cost-cutting and a sharpened focus on its Rice weed management traits.

Cibus, Inc. reported increased revenue and reduced operating cash burn in Q2 2025, driven by strategic streamlining and capital raises, despite a significant net loss and goodwill impairment.

Cibus Inc. announced its Q1 2025 financial results, showcasing advancements in its RTDS technology and regulatory approvals, while also reporting a net loss of $49.4 million and expressing substantial doubt about its ability to continue as a going concern.

Cibus Inc. reported a net loss of $201.5 million for the third quarter of 2024, including a significant goodwill impairment, and announced a strategic realignment to focus on commercialization.

Cibus Inc. announced its second quarter 2024 results, showcasing advancements in its trait development pipeline and commercialization efforts, alongside ongoing financial challenges.

Cibus Inc. announces its fiscal year 2024 results, highlighting progress in crop platforms and a restructuring initiative to prioritize commercial efforts and reduce costs.

Cibus Inc.'s 2023 annual report highlights a strategic shift towards commercialization, marked by a merger, cost reductions, and advancements in its gene editing technology.

Cibus, Inc. CEO Craig Wichner reported transactions involving Class A Common Stock and stock options on June 8, 2026.

Director Mark Terrence Finn was granted 77,586 stock options in Cibus, Inc. as part of a standard equity compensation arrangement.

Director August J. Moretti was granted 77,586 stock options in Cibus, Inc. with an exercise price of $1.39.

Director Rory B. Riggs was granted 77,586 stock options in Cibus, Inc. as part of a standard equity compensation arrangement.

Director Gerhard Prante acquired 64,748 shares of Cibus, Inc. Class A Common Stock via a restricted stock unit grant.

Director Jean-Pierre Jules Lehmann acquired 64,748 shares of Cibus, Inc. Class A Common Stock via a restricted stock unit grant.

Cibus, Inc. has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 2, 2026.

Cibus, Inc. will hold its annual meeting on May 22, 2025, where stockholders will vote on the election of directors, executive compensation, auditor ratification, and several stock-related proposals.

Cibus, Inc. has scheduled its 2025 Annual Meeting of Stockholders for May 22, 2025, to vote on key proposals including the election of directors, executive compensation, and stock issuance matters.

Cibus, Inc. announces its 2024 Annual Meeting of Stockholders to be held on May 30, 2024, with voting open until May 29, 2024, covering the election of directors, executive compensation, and auditor ratification.

Cibus, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 30, 2024, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

Cibus Inc. Chairman Rory B. Riggs has substantially increased his beneficial ownership in the company to 33.02% through multiple direct offerings, warrant exercises, and share exchanges, reinforcing his significant influence as the largest stockholder.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Cibus Inc.'s Class A Common Stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson report a 13.9% beneficial ownership in Cibus Inc.'s Class A Common Stock as of December 31, 2025.

Armistice Capital and Steven Boyd have disclosed a passive beneficial ownership of 4.99% of Cibus, Inc.'s Class A Common Stock.

Armistice Capital, LLC and Steven Boyd have jointly reported a passive beneficial ownership of 5.97% in Cibus, Inc.'s Class A Common Stock, totaling 1,948,000 shares.